Charles Ginsberg1, Joachim H Ix. 1. aDivision of Nephrology-Hypertension, Department of Medicine, University of California San Diego bNephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California cDivision of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego, San Diego, California, USA.
Abstract
PURPOSE OF REVIEW: Higher serum phosphate concentration is a central driver of the chronic kidney disease (CKD) mineral bone disorder (MBD). Although phosphate binders are commonly used to lower phosphate, they are minimally effective in CKD. Nicotinamide (vitamin B3) decreases intestinal phosphate transport in animals. Its efficacy and safety in CKD is uncertain. RECENT FINDINGS: We review data differentiating nicotinamide from nicotinic acid (niacin) and compare the metabolism and side-effect profile of each. Several recent studies have tested the safety and efficacy of nicotinamide in patients with CKD and the general population. Available data on efficacy and safety, gaps in knowledge, and ongoing studies to address them are described. SUMMARY: Nicotinamide is a novel potential tool to treat hyperphosphatemia in patients with CKD, but additional data on safety and efficacy are required before widespread clinical use.
PURPOSE OF REVIEW: Higher serum phosphate concentration is a central driver of the chronic kidney disease (CKD) mineral bone disorder (MBD). Although phosphate binders are commonly used to lower phosphate, they are minimally effective in CKD. Nicotinamide (vitamin B3) decreases intestinal phosphate transport in animals. Its efficacy and safety in CKD is uncertain. RECENT FINDINGS: We review data differentiating nicotinamide from nicotinic acid (niacin) and compare the metabolism and side-effect profile of each. Several recent studies have tested the safety and efficacy of nicotinamide in patients with CKD and the general population. Available data on efficacy and safety, gaps in knowledge, and ongoing studies to address them are described. SUMMARY:Nicotinamide is a novel potential tool to treat hyperphosphatemia in patients with CKD, but additional data on safety and efficacy are required before widespread clinical use.
Authors: Susan C Schiavi; Wen Tang; Christina Bracken; Stephen P O'Brien; Wenping Song; Joseph Boulanger; Susan Ryan; Lucy Phillips; Shiguang Liu; Cynthia Arbeeny; Steven Ledbetter; Yves Sabbagh Journal: J Am Soc Nephrol Date: 2012-08-02 Impact factor: 10.121
Authors: Andrew C Chen; Andrew J Martin; Bonita Choy; Pablo Fernández-Peñas; Robyn A Dalziell; Catriona A McKenzie; Richard A Scolyer; Haryana M Dhillon; Janette L Vardy; Anne Kricker; Gayathri St George; Niranthari Chinniah; Gary M Halliday; Diona L Damian Journal: N Engl J Med Date: 2015-10-22 Impact factor: 91.245
Authors: Conall M O'Seaghdha; Shih-Jen Hwang; Paul Muntner; Michal L Melamed; Caroline S Fox Journal: Nephrol Dial Transplant Date: 2011-02-03 Impact factor: 5.992
Authors: Robert N Foley; Allan J Collins; Charles A Herzog; Areef Ishani; Philip A Kalra Journal: J Am Soc Nephrol Date: 2008-11-05 Impact factor: 10.121
Authors: Michael E Seifert; Lisa de las Fuentes; Marcos Rothstein; Dennis J Dietzen; Andrew J Bierhals; Steven C Cheng; Will Ross; David Windus; Víctor G Dávila-Román; Keith A Hruska Journal: Am J Nephrol Date: 2013-08-07 Impact factor: 3.754
Authors: Rakesh Malhotra; Ronit Katz; Andrew Hoofnagle; Andrew Bostom; Dena E Rifkin; Ruth Mcbride; Jeffrey Probstfield; Geoffrey Block; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2017-12-05 Impact factor: 8.237
Authors: Joachim H Ix; Tamara Isakova; Brett Larive; Kalani L Raphael; Dominic S Raj; Alfred K Cheung; Stuart M Sprague; Linda F Fried; Jennifer J Gassman; John P Middleton; Michael F Flessner; Geoffrey A Block; Myles Wolf Journal: J Am Soc Nephrol Date: 2019-05-13 Impact factor: 10.121